Last reviewed · How we verify
epidoxorubicine, docetaxel, cyclophosphamide
epidoxorubicine, docetaxel, cyclophosphamide is a anthracycline antibiotic, taxane, alkylating agent Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.
Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which ultimately leads to cell death.
Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which ultimately leads to cell death. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.
At a glance
| Generic name | epidoxorubicine, docetaxel, cyclophosphamide |
|---|---|
| Sponsor | Sanofi |
| Drug class | anthracycline antibiotic, taxane, alkylating agent |
| Target | topoisomerase II, microtubules, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epidoxorubicine's mechanism of action is primarily through the inhibition of topoisomerase II, which is essential for DNA replication and cell division. Docetaxel's mechanism involves the stabilization of microtubules, preventing the separation of chromosomes during cell division. Cyclophosphamide's mechanism involves the alkylation of DNA, leading to DNA damage and cell death.
Approved indications
- Metastatic breast cancer
- Metastatic non-small cell lung cancer
- Metastatic ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Stomatitis
- Hair loss
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epidoxorubicine, docetaxel, cyclophosphamide CI brief — competitive landscape report
- epidoxorubicine, docetaxel, cyclophosphamide updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about epidoxorubicine, docetaxel, cyclophosphamide
What is epidoxorubicine, docetaxel, cyclophosphamide?
How does epidoxorubicine, docetaxel, cyclophosphamide work?
What is epidoxorubicine, docetaxel, cyclophosphamide used for?
Who makes epidoxorubicine, docetaxel, cyclophosphamide?
What drug class is epidoxorubicine, docetaxel, cyclophosphamide in?
What development phase is epidoxorubicine, docetaxel, cyclophosphamide in?
What are the side effects of epidoxorubicine, docetaxel, cyclophosphamide?
What does epidoxorubicine, docetaxel, cyclophosphamide target?
Related
- Drug class: All anthracycline antibiotic, taxane, alkylating agent drugs
- Target: All drugs targeting topoisomerase II, microtubules, DNA
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Metastatic non-small cell lung cancer
- Indication: Drugs for Metastatic ovarian cancer
- Compare: epidoxorubicine, docetaxel, cyclophosphamide vs similar drugs
- Pricing: epidoxorubicine, docetaxel, cyclophosphamide cost, discount & access